PCMTD1P2

Across TCGA pan-cancer cohorts, PCMTD1P2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of PCMTD1P2’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where PCMTD1P2 RNA is repressed in tumor relative to normal tissue. In most cancer types PCMTD1P2 is over-expressed in tumor, although a few such as PRAD and THCA show the opposite, repressed pattern.

PRAD and THCA are the cancer types where PCMTD1P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCMTD1P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	−0.021	.022	2	view →
THCA	All	All	−0.037	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

PCMTD1P2–PRAD

Open the PRAD breakdown →